Quick Answer
Celularity Inc reported R&D Expense of $17.39 million for fiscal year 2024.
Celularity Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $17.39M | -42.9% |
| 2023 | $30.46M | -61.1% |
| 2022 | $78.36M | -11.3% |
| 2021 | $88.35M | +67.6% |
| 2020 | $52.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.60M | +17.4% | +37.2% |
| June 30, 2025 | $3.35M | -11.8% | -10.1% |
| March 31, 2025 | $3.73M | -36.2% | -4.8% |
| September 30, 2024 | $3.92M | -24.5% | +3.0% |
| June 30, 2024 | $3.80M | -55.8% | -35.0% |
| March 31, 2024 | $5.84M | -65.5% | +12.8% |
| September 30, 2023 | $5.18M | -74.5% | -39.8% |
| June 30, 2023 | $8.60M | -66.1% | -49.2% |
- Celularity Inc showed a decrease of -42.9% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2024 period, Celularity Inc’s r&d expense has declined by 67.0% (from $52.71 million to $17.39 million).
- The most recent figure is from Celularity Inc’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 8, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: